ALX ONCOLOGY HOLDINGS INC Additional Paid in Capital, Common Stock
ALX ONCOLOGY HOLDINGS INC (ALXO) had Additional Paid in Capital, Common Stock of $894.99 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-06
- 2026-06-30: Additional Paid in Capital, Common Stock $894.99M.
- 2026-03-31: Additional Paid in Capital, Common Stock $892.20M.
- 2025-12-31: Additional Paid in Capital, Common Stock $748.72M.
- 2025-09-30: Additional Paid in Capital, Common Stock $744.67M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $894.99M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $892.20M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $748.72M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $744.67M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $742.15M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $740.00M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $734.41M 10-K · filed 2026-03-09 |
| 2024-09-30 | $728.15M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $720.59M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $685.97M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $675.68M 10-K · filed 2025-03-06 |
| 2023-09-30 | $609.74M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $602.77M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $596.09M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $589.74M 10-K · filed 2024-03-07 |
| 2022-09-30 | $583.18M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $576.97M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $570.68M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $564.99M 10-K · filed 2023-03-09 |
| 2021-09-30 | $558.68M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $553.96M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $551.15M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $548.33M 10-K · filed 2022-02-28 |
| 2020-09-30 | $351.73M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $5.17M 10-Q · filed 2020-08-27 |
| 2019-12-31 | $2.14M 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |